Trials / Completed
CompletedNCT03309150
ATRi Transition Rollover Study
A Rollover Study to Provide Continued Treatment With M6620
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 1 (actual)
- Sponsor
- Merck KGaA, Darmstadt, Germany · Industry
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
The main purpose of the study was to monitor the safety of participant receiving long-term treatment of Berzosertib as monotherapy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Berzosertib | Participants received intravenous infusion of Berzosertib at a dose of 126 milligrams (mg) on Days 1, 8 and 15 until disease progression or unacceptable toxicity occurred. |
Timeline
- Start date
- 2018-01-10
- Primary completion
- 2024-01-26
- Completion
- 2024-01-26
- First posted
- 2017-10-13
- Last updated
- 2024-11-29
- Results posted
- 2024-11-29
Locations
1 site across 1 country: United Kingdom
Source: ClinicalTrials.gov record NCT03309150. Inclusion in this directory is not an endorsement.